These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21216118)

  • 41. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [A case of sudden-onset hearing loss in a patient treated with peginterferon alpha-2b and ribavirin for chronic hepatitis C].
    Shin MK; Kim TH; Ju K; Ha CY; Min HJ; Jung WT; Lee OJ
    Korean J Hepatol; 2009 Sep; 15(3):370-4. PubMed ID: 19783887
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Observation on effect of peg interferon lphaa-2a treating lamivudine resistant chronic hepatitis B].
    Bai HL; Luo HT; Ye YN; Long H; Zhong RX
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Jun; 24(3):230-1. PubMed ID: 21186536
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
    Ogawa E; Furusyo N; Kajiwara E; Takahashi K; Nomura H; Tanabe Y; Satoh T; Maruyama T; Nakamuta M; Kotoh K; Azuma K; Dohmen K; Shimoda S; Hayashi J;
    J Gastroenterol Hepatol; 2012 Jul; 27(7):1233-40. PubMed ID: 22098185
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.
    Buster EH; Flink HJ; Cakaloglu Y; Simon K; Trojan J; Tabak F; So TM; Feinman SV; Mach T; Akarca US; Schutten M; Tielemans W; van Vuuren AJ; Hansen BE; Janssen HL
    Gastroenterology; 2008 Aug; 135(2):459-67. PubMed ID: 18585385
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Virodynamic predictors of response to pegylated interferon and lamivudine combination treatment of hepatitis B e antigen-positive chronic hepatitis B.
    Mihm U; Chan HL; Zeuzem S; Chim AM; Hui AY; Wong VW; Sung JJ; Herrmann E
    Antivir Ther; 2008; 13(8):1029-37. PubMed ID: 19195328
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.
    Bonino F; Marcellin P; Lau GK; Hadziyannis S; Jin R; Piratvisuth T; Germanidis G; Yurdaydin C; Diago M; Gurel S; Lai MY; Brunetto MR; Farci P; Popescu M; McCloud P;
    Gut; 2007 May; 56(5):699-705. PubMed ID: 17127704
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B.
    Chan HL; Hui AY; Wong VW; Chim AM; Wong ML; Sung JJ
    Hepatology; 2005 Jun; 41(6):1357-64. PubMed ID: 15880608
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Summaries for patients. Combination therapy for chronic hepatitis B.
    Ann Intern Med; 2005 Feb; 142(4):I30. PubMed ID: 15710953
    [No Abstract]   [Full Text] [Related]  

  • 50. [Therapy of recurrent hepatitis B infection after liver transplantation. A retrospective analysis of 200 liver transplantations based on hepatitis B associated liver diseases].
    Seehofer D; Rayes N; Bechstein WO; Naumann U; Neuhaus R; Berg T; Hopf U; Langrehr JM; Steinmüller T; Platz KP; Müller AR; Neuhaus P
    Z Gastroenterol; 2000 Sep; 38(9):773-83. PubMed ID: 11072673
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment with interferons (including pegylated interferons) in patients with hepatitis B.
    Cooksley WG
    Semin Liver Dis; 2004; 24 Suppl 1():45-53. PubMed ID: 15192801
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
    Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
    J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [A multicenter, randomized, open-label study of the safety and effectiveness of pegylated interferon alpha 2b and interferon alpha 2b in treating HBeAg positive chronic hepatitis B patients].
    Zhao H; Si CW; Wei L; Wan MB; Ying YK; Hou JL; Niu JQ
    Zhonghua Gan Zang Bing Za Zhi; 2006 May; 14(5):323-6. PubMed ID: 16732903
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pretreatment with pegylated interferon prevents emergence of lamivudine mutants in lamivudine-naive patients: a pilot study.
    Villa E; Lei B; Taliani G; Graziosi A; Critelli R; Luongo M; Gennari W; Bianchini M; Ferretti I
    Antivir Ther; 2009; 14(8):1081-7. PubMed ID: 20032538
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B.
    Sarin SK; Sood A; Kumar M; Arora A; Amrapurkar D; Sharma BC; Konar A; Chawla YK; Jain RK; Nanda V; Kumar A; Hissar S; Lavate P; Lahoti D;
    Am J Gastroenterol; 2007 Jan; 102(1):96-104. PubMed ID: 17266689
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low incidence of retinopathy during peginterferon alpha-2b and lamivudine therapy for chronic hepatitis B.
    Buster EH; Ter Borg MJ; Vingerling JR; Janssen HL
    J Hepatol; 2006 Jul; 45(1):160-1; author reply 161-2. PubMed ID: 16723166
    [No Abstract]   [Full Text] [Related]  

  • 57. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy.
    Flink HJ; Sprengers D; Hansen BE; van Zonneveld M; de Man RA; Schalm SW; Janssen HL;
    Gut; 2005 Nov; 54(11):1604-9. PubMed ID: 15923670
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
    Gluhovschi C; Gadalean F; Kaycsa A; Curescu M; Sporea I; Gluhovschi G; Petrica L; Velciov S; Bozdog G; Bob F; Vernic C; Cioca D
    Immunopharmacol Immunotoxicol; 2011 Dec; 33(4):744-50. PubMed ID: 21320001
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy.
    Marcellin P; Wursthorn K; Wedemeyer H; Chuang WL; Lau G; Avila C; Peng CY; Gane E; Lim SG; Fainboim H; Foster GR; Safadi R; Rizzetto M; Manns M; Bao W; Trylesinski A; Naoumov N
    J Hepatol; 2015 Jan; 62(1):41-7. PubMed ID: 25152207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.